Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by Analysts

Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nineteen ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $74.47.

Several brokerages have issued reports on EXAS. Stifel Nicolaus reduced their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Robert W. Baird dropped their price target on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Sanford C. Bernstein upped their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Citigroup decreased their target price on shares of Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Finally, Piper Sandler reduced their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th.

Exact Sciences Price Performance

EXAS stock traded up $4.38 during trading on Tuesday, reaching $53.92. 2,823,268 shares of the company were exchanged, compared to its average volume of 2,647,685. The company has a market cap of $9.98 billion, a P/E ratio of -45.43 and a beta of 1.27. Exact Sciences has a 52-week low of $40.62 and a 52-week high of $79.62. The stock's 50 day moving average price is $65.64 and its 200 day moving average price is $56.08. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analysts' expectations of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Exact Sciences's quarterly revenue was up 12.8% compared to the same quarter last year. As a group, analysts predict that Exact Sciences will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Brian Baranick sold 929 shares of the firm's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 13,687 shares in the company, valued at $958,090. This trade represents a 6.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin T. Conroy bought 19,500 shares of the stock in a transaction on Wednesday, November 13th. The stock was acquired at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the acquisition, the chief executive officer now owns 1,074,191 shares of the company's stock, valued at $55,159,707.85. This represents a 1.85 % increase in their position. The disclosure for this purchase can be found here. 1.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Huntington National Bank grew its stake in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after purchasing an additional 352 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Exact Sciences during the 2nd quarter worth about $29,000. RPg Family Wealth Advisory LLC purchased a new stake in Exact Sciences during the 3rd quarter worth about $34,000. Capital Performance Advisors LLP purchased a new stake in Exact Sciences during the 3rd quarter worth about $35,000. Finally, Vestor Capital LLC purchased a new stake in Exact Sciences during the 3rd quarter worth about $46,000. Institutional investors own 88.82% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.